NORD gratefully acknowledges Anne W. Lucky, MD, Children's Hospital of Cincinnati, Brett Koplen, Executive Director, DebRA of America, Inc., and Geraldine Kelly-Mancuso, RN, DEBRA Nurse Educator, Cincinnati Children's Hospital Medical Center, for assistance in the preparation of this report.
Epidermolysis bullosa (EB) is a genetic skin disorder characterized clinically by blister formation from mechanical trauma. There are four main types with additional sub-types identified. There is a spectrum of severity, and within each type, one may be either mildly or severely affected. EB ranges from being a minor inconvenience requiring modification of some activities, to being completely disabling and, in some cases, fatal.
Friction causes blister formation. Blisters can form anywhere on the surface of the skin, within the oral cavity and in more severe forms may also involve the external surface of the eye, as well as the respiratory, gastrointestinal and genitourinary tracts. In some forms of the disease, disfiguring scars and disabling musculoskeletal deformities occur.
Currently, there is no cure for EB. Supportive care includes daily wound care, bandaging, and pain management as needed.
Epidermolysis bullosa is divided into four subdivisions, and each subdivision has subtypes.
Epidermolysis bullosa simplex (EBS) is usually dominantly inherited, and involves disorders of the genes for Keratins 5 and 14 and plectin. Recently, several suprabasal types of EBS have been described as well. Blistering occurs within the uppermost layer of the skin, the epidermis. EBS may be localized to the hands and feet or there may be a generalized distribution, with relatively mild internal involvement. Those with EBS may have thickened calluses on the palms and soles, oral blistering during infancy and rough, thickened fingernails/toenails. EBS does not usually scar. There are rare recessive forms. EBS with plectin mutations may be associated with muscular dystrophy.
Junctional epidermolysis bullosa (JEB), is recessively inherited, and involves mutations in the genes for several components of the junction between the epidermis and dermis such as Laminin 332 (previously known as Laminin 5), plectin, and a6b4integrin. There are two major subtypes, Herlitz JEB and JEB- other (includes non-Herlitz JEB, and JEB with pyloric atresia and several other subtypes). Junctional Herlitz EB is due to mutations in any of the three Laminin 332 chains and can be a very severe form of EB. Death often occurs during infancy due to overwhelming infection (sepsis), malnutrition, dehydration, electrolyte imbalance or obstructive airway complications. There is a wide spectrum of JEB- O. Oral cavity involvement and irregular pitting of the surfaces of the teeth is common in all subtypes. Infants presenting with pyloric atresia will have trouble with feeding and abdominal distension as neonates and present as surgical emergencies in the newborn period.
Dystrophic epidermolysis bullosa (DEB) can be either dominantly or recessively inherited, and involves defects in Type VII collagen. Blisters occur within the lower layer of the skin, the dermis. There are two major subtypes, dominant DEB (DDEB) and recessive DEB (RDEB).
Dominant dystrophic EB (DDEB): DDEB is usually mild. Blistering may be localized to the hands, feet, elbows and knees or it may be generalized. Common findings include scarring, milia (tiny white bumps), mucous membrane involvement, and abnormal or absent nails. Some family members may only have nail dystrophy.
Recessive dystrophic EB (RDEB): RDEB is typically more generalized and severe than DDEB. In addition to scarring, milia, mucous membrane involvement and nail dystrophy, common manifestations include malnutrition, anemia, esophageal strictures, growth retardation, webbing or fusion of the fingers and toes causing mitten deformity (pseudosyndactyly) with loss of function, development of contractures, malformation of teeth, microstomia and corneal abrasions. Severe generalized RDEB (formerly Hallopeau-Siemens RDEB) tends to be the most severe form.
Kindler syndrome is very rare and involves all layers of the skin with extreme fragility.
Inherited epidermolysis bullosa is the focus of this report. The inherited forms follow either autosomal dominant or autosomal recessive inheritance. There is also a rare acquired autoimmune disorder called epidermolysis bullosa aquisita. A mutation in any of at least 18 genes encoding the proteins in the epidermis, basement membrane or dermis causes poor integrity of the skin leading to fragility.
Recessive genetic disorders occur when an individual inherits two copies of an abnormal gene for the same trait, one from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease but usually will not show symptoms. The risk for two carrier parents to both pass the defective gene and have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25%. The risk is the same for males and females.
All individuals carry at least 4-5 abnormal genes. Parents who are close relatives (consanguineous) have a higher chance than unrelated parents to both carry the same abnormal gene, which increases the risk to have children with a recessive genetic disorder.
Dominant genetic disorders occur when only a single copy of an abnormal gene is necessary to cause a particular disease. The abnormal gene can be inherited from either parent or can be the result of a new mutation (gene change) in the affected individual. The risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy. The risk is the same for males and females.
Some type of EB occurs in an estimated 1 out of every 50,000 live births. The disorder occurs in every racial and ethnic group throughout the world and affects both sexes equally.
Clinical diagnosis of the type of EB based on presentation in the neonatal period should be avoided as all types of EB may look alike in this age group. When EB is suspected, a skin biopsy should be obtained and sent to an appropriate laboratory to confirm the diagnosis with transmission electron microscopy (TEM) and/or immunofluorescent antibody/antigen mapping. Molecular genetic testing for mutations in most of the genes known to be associated with the various types of EB is clinically available.
By definition, inherited EB is a genetically transmitted disorder characterized by marked fragility of the skin. Any trauma, no matter how minimal it may seem, is likely to cause the skin of an EB child or adult to tear or blister. The following are recommended ways to avoid or minimize this problem:
Stem cell transplant therapy trials for recessive dystrophic epidermolysis bullosa are being conducted at at least two institutions. For further information contact the following :
University of Minnesota Center for Translational Medicine
Dr. Christen Ebens 612-273-2800 Toll-free: 1-888-601-0787
Cincinnati Children’s Hospital
Epidermolysis Bullosa Center
Anne W. Lucky, MD or Richard G. Azizkhan, MD
(Severe Junctional EB) Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office: Tollfree: (800) 411-1222 TTY: (866) 411-1010 Email: [email protected]
For information about clinical trials sponsored by private sources, contact: www.centerwatch.com
For information about clinical trials conducted in Europe, contact:
RareConnect offers a safe patient-hosted online community for patients and caregivers affected by this rare disease. For more information, visit www.rareconnect.org.
Fine JD, Hintner H., eds. Life with Epidermolysis Bullosa (EB): Etiology, Diagnosis, Multidisciplinary Care and Therapy, New York: Springer Wien; 2009.
Fine JD, Bauer E, McGuire J , Moshell A, eds.Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry 1st edition The Johns Hopkins University Press; 1999.
Weston WL, Lane AT, Morelli JG, eds. Color Textbook of Pediatric Dermatology, 4th Edition Mosby/Elsevier, 2007: 348-354.
Murrell DF (ed.) (2010): Epidermolysis Bullosa: Part I – Pathogenesis and Clinical Features. Dermatologic Clinics, Vol 28/1. Philadelphia: W.B. Saunders Elsevier.
Murrell DF (ed.) (2010): Epidermolysis Bullosa: Part II – Diagnosis and Management. Dermatologic Clinics, Vol 28/2. Philadelphia: W.B. Saunders Elsevier.
Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues.
J Am Acad Dermatol. 2009 Sep;61(3):367-84.
Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol. 2009 Sep;61(3):387-402.
Pfendne EG, Bruckner A, Conget P, Mellerio J, Palisson F, Lucky AW. Basic science of epidermolysis bullosa and diagnostic and molecular characterization: Proceedings of the IInd International Symposium on Epidermolysis Bullosa. Santiago, Chile, 2005 International Journal of Dermatology. 2007; 46(8):781-794.
Azizkhan RG, Denyer JE, Mellerio JE, González R, Bacigalupo M, Kantor A, Passalacqua G, Palisson F, Lucky AW. Surgical management of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005. International Journal of Dermatology. 2007:46(8): 801-808.
Mellerio JE, Weiner M, Denyer JE, Pillay EI, Lucky AW, Bruckner A, Palisson F. Medical management of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005 International Journal of Dermatology 2007;46(8): 795- 800.
Lucky AW, Pfendner E, Pillay E, Paskel J, Weiner M, Palisson F. Psychosocial aspects of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005 International Journal of Dermatology. 2007;46(8): 809-814.
Debra International. Caring for Someone with EB. Available at: http://www.debra-international.org/patients/caring-for-someone-with-eb.html Accessed May 30, 2013.
Marinkovich MP. Epidermolysis Bullosa Updated: Aug. 10, 2012. Medscape. Available at: http://emedicine.medscape.com/article/1062939-overview Accessed May 30, 2013.
Pfendner E, Bruckner A. Epidermolysis Bullosa Simplex. Last Update Sept. 1, 2011. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2013. Available at http://www.genetests.org . Accessed May 30, 2013.
Pfendner E, Lucky AW. Dystrophic Epidermolysis Bullosa. Last Update Nov 4, 2010. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2013. Available at http://www.genetests.org . Accessed May 30, 2013.
Pfendner E, Lucky AW. Junctional Epidermolysis Bullosa. Posted: Feb 2, 2008. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2013. Available at http://www.genetests.org . Accessed May 30, 2013.
Pfendner E, Lucky AW. Epidermolysis Bullosa with Pyloric Atresia. Last Update: February 14, 2013. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2013. Available at http://www.genetests.org Accessed May 30, 2013.
The information in NORD’s Rare Disease Database is for educational purposes only and is not intended to replace the advice of a physician or other qualified medical professional.
The content of the website and databases of the National Organization for Rare Disorders (NORD) is copyrighted and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial or public purpose, without prior written authorization and approval from NORD. Individuals may print one hard copy of an individual disease for personal use, provided that content is unmodified and includes NORD’s copyright.
National Organization for Rare Disorders (NORD)
55 Kenosia Ave., Danbury CT 06810 • (203)744-0100